Inactivation of Intergenic Enhancers by EBNA3A Initiates and Maintains Polycomb Signatures across a Chromatin Domain Encoding CXCL10 and CXCL9

PLoS Pathogens

Volumn 9, Issue 9, 2013, Pages

  Harth Hertle, Marie L ^a   Scholz, Barbara A ^a   Erhard, Florian ^b   Glaser, Laura V ^a   Dölken, Lars ^c   Zimmer, Ralf ^b   Kempkes, Bettina ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CXCL9 CHEMOKINE; EPSTEIN BARR VIRUS ANTIGEN 2; EPSTEIN BARR VIRUS ANTIGEN 3A; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HISTONE H3; POLYCOMB GROUP PROTEIN; PROTEIN P16; SPACER DNA; UNCLASSIFIED DRUG; VIRUS ANTIGEN; CXCL10 PROTEIN, HUMAN; CXCL9 PROTEIN, HUMAN; EBNA-2 PROTEIN, HUMAN HERPESVIRUS 4; EBNA-3A ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; IMMUNOGLOBULIN J RECOMBINATION SIGNAL SEQUENCE BINDING PROTEIN; RBPJ PROTEIN, HUMAN; RECOMBINANT PROTEIN; REPRESSOR PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS PROTEIN;

ARTICLE; BIOINFORMATICS; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; ENHANCER REGION; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN GENOME; NONHUMAN; POLYMERASE CHAIN REACTION; WESTERN BLOTTING; B LYMPHOCYTE; BIOLOGICAL MODEL; CELL LINE; CHROMATIN ASSEMBLY AND DISASSEMBLY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; MUTATION; NUCLEAR REPROGRAMMING; VIROLOGY;

B-LYMPHOCYTES; CELL LINE; CELLULAR REPROGRAMMING; CHEMOKINE CXCL10; CHEMOKINE CXCL9; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA, INTERGENIC; ENHANCER ELEMENTS, GENETIC; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOGLOBULIN J RECOMBINATION SIGNAL SEQUENCE-BINDING PROTEIN; MODELS, BIOLOGICAL; MUTATION; POLYCOMB-GROUP PROTEINS; RECOMBINANT PROTEINS; REPRESSOR PROTEINS; TRANS-ACTIVATORS; VIRAL PROTEINS;

EID: 84884692313     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003638     Document Type: Article

References (100)

1. Rickinson AB, Kieff E (2007) Epstein-Barr virus. In: David PMH, Knipe M, Griffin DE, Lamb RA, Martin MA et al., editors. Fields virology. Philadelphia: Lippincott-Raven Publishers. pp. 2655-2700.
2. Kieff E, Rickinson AB (2007) Epstein-Barr virus and its replication. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA et al., editors. Fields Virology. Philadelphia: Lippincott Williams and Wilkins. pp. 2603-2654.
3. Young LS, Rickinson AB, (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-768.
4. Thorley-Lawson DA, (2001) Epstein-Barr virus: exploiting the immune system. Nature Rev Immunol 1: 75-82.
5. Thorley-Lawson DA, Gross A, (2004) Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350: 1328-1337.
6. Bain M, Watson RJ, Farrell PJ, Allday MJ, (1996) Epstein-Barr virus nuclear antigen 3C is a powerful repressor of transcription when tethered to DNA. J Virol 70: 2481-2489.
7. Bourillot PY, Waltzer L, Sergeant A, Manet E, (1998) Transcriptional repression by the Epstein-Barr virus EBNA3A protein tethered to DNA does not require RBP-Jkappa. J Gen Virol 79: 363-370.
8. Cludts I, Farrell PJ, (1998) Multiple functions within the Epstein-Barr virus EBNA-3A protein. J Virol 72: 1862-1869.
9. Hickabottom M, Parker GA, Freemont P, Crook T, Allday MJ, (2002) Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxyl-terminal-binding protein (CtBP). J Biol Chem 277: 47197-47204.
10. Touitou R, Hickabottom M, Parker G, Crook T, Allday MJ, (2001) Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C. J Virol 75: 7749-7755.
11. Radkov SA, Touitou R, Brehm A, Rowe M, West M, et al. (1999) Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J Virol 73: 5688-5697.
12. Knight JS, Lan K, Subramanian C, Robertson ES, (2003) Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J Virol 77: 4261-4272.
13. Kopan R, Ilagan MX, (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137: 216-233.
14. Le Roux A, Kerdiles B, Walls D, Dedieu JF, Perricaudet M, (1994) The Epstein-Barr virus determined nuclear antigens EBNA-3A,-3B, and-3C repress EBNA-2-mediated transactivation of the viral terminal protein 1 gene promoter. Virology 205: 596-602.
15. Marshall D, Sample C, (1995) Epstein-Barr virus nuclear antigen 3C is a transcriptional regulator. J Virol 69: 3624-3630.
16. Waltzer L, Perricaudet M, Sergeant A, Manet E, (1996) Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA. J Virol 70: 5909-5915.
17. Radkov SA, Bain M, Farrell PJ, West M, Rowe M, et al. (1997) Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J Virol 71: 8552-8562.
18. Robertson ES, Grossman S, Johannsen E, Miller C, Lin J, et al. (1995) Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa. J Virol 69: 3108-3116.
19. Zhao B, Zou J, Wang H, Johannsen E, Peng CW, et al. (2011) Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth. Proc Natl Acad Sci U S A 108: 14902-14907.
20. Bulger M, Groudine M, (2011) Functional and mechanistic diversity of distal transcription enhancers. Cell 144: 327-339.
21. Ong CT, Corces VG, (2011) Enhancer function: new insights into the regulation of tissue-specific gene expression. Nat Rev Genet 12: 283-293.
22. Zentner GE, Scacheri PC, (2012) The chromatin fingerprint of gene enhancer elements. J Biol Chem 287: 30888-30896.
23. Cooper A, Johannsen E, Maruo S, Cahir-McFarland E, Illanes D, et al. (2003) EBNA3A association with RBP-Jkappa down-regulates c-myc and Epstein-Barr virus-transformed lymphoblast growth. J Virol 77: 999-1010.
24. Hertle ML, Popp C, Petermann S, Maier S, Kremmer E, et al. (2009) Differential gene expression patterns of EBV infected EBNA-3A positive and negative human B lymphocytes. PLoS Pathog 5: e1000506.
25. Zhao B, Mar JC, Maruo S, Lee S, Gewurz BE, et al. (2011) Epstein-Barr virus nuclear antigen 3C regulated genes in lymphoblastoid cell lines. Proc Natl Acad Sci U S A 108: 337-342.
26. Chen A, Zhao B, Kieff E, Aster JC, Wang F, (2006) EBNA-3B- and EBNA-3C-regulated cellular genes in Epstein-Barr virus-immortalized lymphoblastoid cell lines. J Virol 80: 10139-10150.
27. White RE, Groves IJ, Turro E, Yee J, Kremmer E, et al. (2010) Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification. PLoS One 5: e13979.
28. Young P, Anderton E, Paschos K, White R, Allday MJ, (2008) Epstein-Barr virus nuclear antigen (EBNA) 3A induces the expression of and interacts with a subset of chaperones and co-chaperones. J Gen Virol 89: 866-877.
29. McClellan MJ, Khasnis S, Wood CD, Palermo RD, Schlick SN, et al. (2012) Downregulation of integrin receptor-signaling genes by Epstein-Barr virus EBNA 3C via promoter-proximal and-distal binding elements. J Virol 86: 5165-5178.
30. Skalska L, White RE, Parker GA, Sinclair AJ, Paschos K, et al. (2013) Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines. PLoS Pathog 9: e1003187.
31. Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, et al. (2011) Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci U S A 108: 1919-1924.
32. Paschos K, Parker GA, Watanatanasup E, White RE, Allday MJ, (2012) BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV. Nucleic Acids Res 40: 7233-7246.
33. Skalska L, White RE, Franz M, Ruhmann M, Allday MJ, (2010) Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog 6: e1000951.
34. Margueron R, Reinberg D, (2011) The Polycomb complex PRC2 and its mark in life. Nature 469: 343-349.
35. Beisel C, Paro R, (2011) Silencing chromatin: comparing modes and mechanisms. Nat Rev Genet 12: 123-135.
36. Sing A, Pannell D, Karaiskakis A, Sturgeon K, Djabali M, et al. (2009) A vertebrate Polycomb response element governs segmentation of the posterior hindbrain. Cell 138: 885-897.
37. Woo CJ, Kharchenko PV, Daheron L, Park PJ, Kingston RE, (2010) A region of the human HOXD cluster that confers polycomb-group responsiveness. Cell 140: 99-110.
38. Ku M, Koche RP, Rheinbay E, Mendenhall EM, Endoh M, et al. (2008) Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet 4: e1000242.
39. Lynch MD, Smith AJH, De Gobbi M, Flenley M, Hughes JR, et al. (2012) An interspecies analysis reveals a key role for unmethylated CpG dinucleotides in vertebrate Polycomb complex recruitment. Embo Journal 31: 317-329.
40. Mendenhall EM, Koche RP, Truong T, Zhou VW, Issac B, et al. (2010) GC-rich sequence elements recruit PRC2 in mammalian ES cells. PLoS Genet 6: e1001244.
41. Taberlay PC, Kelly TK, Liu CC, You JS, De Carvalho DD, et al. (2011) Polycomb-Repressed Genes Have Permissive Enhancers that Initiate Reprogramming. Cell 147: 1283-1294.
42. Vernimmen D, Lynch MD, De Gobbi M, Garrick D, Sharpe JA, et al. (2011) Polycomb eviction as a new distant enhancer function. Genes & Development 25: 1583-1588.
43. Consortium EP, (2011) A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 9: e1001046.
44. Consortium EP, Dunham I, Kundaje A, Aldred SF, Collins PJ, et al. (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489: 57-74.
45. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, et al. (1996) Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184: 963-969.
46. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, et al. (2007) The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 21: 525-530.
47. Popov N, Gil J, (2010) Epigenetic regulation of the INK4b-ARF-INK4a locus: in sickness and in health. Epigenetics 5: 685-690.
48. Bornkamm GW, Berens C, Kuklik-Roos C, Bechet JM, Laux G, et al. (2005) Stringent doxycycline-dependent control of gene activities using an episomal one-vector system. Nucleic Acids Res 33: e137.
49. Melvin WT, Milne HB, Slater AA, Allen HJ, Keir HM, (1978) Incorporation of 6-thioguanosine and 4-thiouridine into RNA. Application to isolation of newly synthesised RNA by affinity chromatography. Eur J Biochem 92: 373-379.
50. Dolken L, Ruzsics Z, Radle B, Friedel CC, Zimmer R, et al. (2008) High-resolution gene expression profiling for simultaneous kinetic parameter analysis of RNA synthesis and decay. RNA 14: 1959-1972.
51. Spender LC, Lucchesi W, Bodelon G, Bilancio A, Karstegl CE, et al. (2006) Cell target genes of Epstein-Barr virus transcription factor EBNA-2: induction of the p55alpha regulatory subunit of PI3-kinase and its role in survival of EREB2.5 cells. J Gen Virol 87: 2859-2867.
52. Wang H, Zou J, Zhao B, Johannsen E, Ashworth T, et al. (2011) Genome-wide analysis reveals conserved and divergent features of Notch1/RBPJ binding in human and murine T-lymphoblastic leukemia cells. Proc Natl Acad Sci U S A 108: 14908-14913.
53. Lucchesi W, Brady G, Dittrich-Breiholz O, Kracht M, Russ R, et al. (2008) Differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2. J Virol 82: 7456-7466.
54. Touitou R, O'Nions J, Heaney J, Allday MJ, (2005) Epstein-Barr virus EBNA3 proteins bind to the C8/alpha7 subunit of the 20S proteasome and are degraded by 20S proteasomes in vitro, but are very stable in latently infected B cells. J Gen Virol 86: 1269-1277.
55. Maier S, Santak M, Mantik A, Grabusic K, Kremmer E, et al. (2005) A somatic knockout of CBF1 in a human B-cell line reveals that induction of CD21 and CCR7 by EBNA-2 is strictly CBF1 dependent and that downregulation of immunoglobulin M is partially CBF1 independent. J Virol 79: 8784-8792.
56. Ernst J, Kellis M, (2010) Discovery and characterization of chromatin states for systematic annotation of the human genome. Nat Biotechnol 28: 817-825.
57. Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, et al. (2011) Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473: 43-49.
58. Xi H, Shulha HP, Lin JM, Vales TR, Fu Y, et al. (2007) Identification and characterization of cell type-specific and ubiquitous chromatin regulatory structures in the human genome. PLoS Genet 3: e136.
59. Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, et al. (2007) Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 39: 311-318.
60. Visel A, Blow MJ, Li Z, Zhang T, Akiyama JA, et al. (2009) ChIP-seq accurately predicts tissue-specific activity of enhancers. Nature 457: 854-858.
61. Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, et al. (2009) Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459: 108-112.
62. Koch CM, Andrews RM, Flicek P, Dillon SC, Karaoz U, et al. (2007) The landscape of histone modifications across 1% of the human genome in five human cell lines. Genome Res 17: 691-707.
63. Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, et al. (2010) Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A 107: 21931-21936.
64. Rada-Iglesias A, Bajpai R, Swigut T, Brugmann SA, Flynn RA, et al. (2011) A unique chromatin signature uncovers early developmental enhancers in humans. Nature 470: 279-283.
65. Zentner GE, Tesar PJ, Scacheri PC, (2011) Epigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions. Genome Res 21: 1273-1283.
66. De Santa F, Barozzi I, Mietton F, Ghisletti S, Polletti S, et al. (2010) A large fraction of extragenic RNA pol II transcription sites overlap enhancers. PLoS Biol 8: e1000384.
67. Kim TK, Hemberg M, Gray JM, Costa AM, Bear DM, et al. (2010) Widespread transcription at neuronal activity-regulated enhancers. Nature 465: 182-187.
68. Koch F, Fenouil R, Gut M, Cauchy P, Albert TK, et al. (2011) Transcription initiation platforms and GTF recruitment at tissue-specific enhancers and promoters. Nat Struct Mol Biol 18: 956-963.
69. Koch F, Andrau JC, (2011) Initiating RNA polymerase II and TIPs as hallmarks of enhancer activity and tissue-specificity. Transcription 2: 263-268.
70. Thapa M, Welner RS, Pelayo R, Carr DJ, (2008) CXCL9 and CXCL10 expression are critical for control of genital herpes simplex virus type 2 infection through mobilization of HSV-specific CTL and NK cells to the nervous system. J Immunol 180: 1098-1106.
71. Wuest TR, Carr DJ, (2008) Dysregulation of CXCR3 signaling due to CXCL10 deficiency impairs the antiviral response to herpes simplex virus 1 infection. J Immunol 181: 7985-7993.
72. Thapa M, Carr DJ, (2009) CXCR3 deficiency increases susceptibility to genital herpes simplex virus type 2 infection: Uncoupling of CD8+ T-cell effector function but not migration. J Virol 83: 9486-9501.
73. Bartee E, Mohamed MR, McFadden G, (2008) Tumor necrosis factor and interferon: cytokines in harmony. Curr Opin Microbiol 11: 378-383.
74. Maier S, Staffler G, Hartmann A, Hock J, Henning K, et al. (2006) Cellular target genes of Epstein-Barr virus nuclear antigen 2. J Virol 80: 9761-9771.
75. White RE, Ramer PC, Naresh KN, Meixlsperger S, Pinaud L, et al. (2012) EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest 122: 1487-1502.
76. Calderwood MA, Venkatesan K, Xing L, Chase MR, Vazquez A, et al. (2007) Epstein-Barr virus and virus human protein interaction maps. Proc Natl Acad Sci U S A 104: 7606-7611.
77. Anderton E, Yee J, Smith P, Crook T, White RE, et al. (2008) Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene 27: 421-433.
78. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, et al. (2009) Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog 5: e1000492.
79. Maruo S, Johannsen E, Illanes D, Cooper A, Kieff E, (2003) Epstein-Barr Virus nuclear protein EBNA3A is critical for maintaining lymphoblastoid cell line growth. J Virol 77: 10437-10447.
80. Maruo S, Wu Y, Ishikawa S, Kanda T, Iwakiri D, et al. (2006) Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells. Proc Natl Acad Sci U S A 103: 19500-19505.
81. Collins PL, Henderson MA, Aune TM, (2012) Lineage-specific adjacent IFNG and IL26 genes share a common distal enhancer element. Genes Immun 13: 481-488.
82. Spitz F, Duboule D, (2008) Global control regions and regulatory landscapes in vertebrate development and evolution. Adv Genet 61: 175-205.
83. Wang D, Garcia-Bassets I, Benner C, Li W, Su X, et al. (2011) Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474: 390-394.
84. Natoli G, Andrau JC, (2012) Noncoding transcription at enhancers: general principles and functional models. Annu Rev Genet 46: 1-19.
85. Demers C, Chaturvedi CP, Ranish JA, Juban G, Lai P, et al. (2007) Activator-mediated recruitment of the MLL2 methyltransferase complex to the beta-globin locus. Mol Cell 27: 573-584.
86. Fromm G, Cadiz-Rivera B, de Vries C, Getman M, McGrath KE, et al. (2011) An embryonic stage-specific enhancer within the murine beta-globin locus mediates domain-wide histone hyperacetylation. Blood 117: 5207-5214.
87. Martinez AM, Schuettengruber B, Sakr S, Janic A, Gonzalez C, et al. (2009) Polyhomeotic has a tumor suppressor activity mediated by repression of Notch signaling. Nat Genet 41: 1076-1082.
88. Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, et al. (2012) Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 18: 298-301.
89. Klymenko T, Muller J, (2004) The histone methyltransferases Trithorax and Ash1 prevent transcriptional silencing by Polycomb group proteins. EMBO Rep 5: 373-377.
90. Tie F, Banerjee R, Stratton CA, Prasad-Sinha J, Stepanik V, et al. (2009) CBP-mediated acetylation of histone H3 lysine 27 antagonizes Drosophila Polycomb silencing. Development 136: 3131-3141.
91. Kia SK, Gorski MM, Giannakopoulos S, Verrijzer CP, (2008) SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. Mol Cell Biol 28: 3457-3464.
92. Ringrose L, Paro R, (2004) Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet 38: 413-443.
93. Schmitt S, Prestel M, Paro R, (2005) Intergenic transcription through a polycomb group response element counteracts silencing. Genes Dev 19: 697-708.
94. Yuan W, Xu M, Huang C, Liu N, Chen S, et al. (2011) H3K36 methylation antagonizes PRC2-mediated H3K27 methylation. J Biol Chem 286: 7983-7989.
95. Schmitges FW, Prusty AB, Faty M, Stutzer A, Lingaraju GM, et al. (2011) Histone methylation by PRC2 is inhibited by active chromatin marks. Mol Cell 42: 330-341.
96. Pekowska A, Benoukraf T, Zacarias-Cabeza J, Belhocine M, Koch F, et al. (2011) H3K4 tri-methylation provides an epigenetic signature of active enhancers. Embo Journal 30: 4198-4210.
97. Ben-Bassat H, Goldblum N, Mitrani S, Goldblum T, Yoffey JM, et al. (1977) Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75). Int J Cancer 19: 27-33.
98. Schneider CA, Rasband WS, Eliceiri KW, (2012) NIH Image to ImageJ: 25 years of image analysis. Nature Methods 9: 671-675.
99. Ciccone DN, Morshead KB, Oettinger MA, (2004) Chromatin immunoprecipitation in the analysis of large chromatin domains across murine antigen receptor loci. Methods Enzymol 376: 334-348.
100. Kovall RA, Hendrickson WA, (2004) Crystal structure of the nuclear effector of Notch signaling, CSL, bound to DNA. Embo J 23: 3441-3451.